Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same

• US 20030229009A1
• Filed: 03/05/2003
• Published: 12/11/2003
• Est. Priority Date: 09/07/2001
• Status: Active Grant

• Current Assignee: Biocon Limited (Biocon Incorporated)
• Original Assignee: Biocon Limited (Biocon Incorporated)
• Inventors: Radhakrishnan, Balasingam, Ekwuribe, Nnochiri N., Soltero, Richard
• Granted Patent: US 7,166,571 B2
• Time in Patent Office: Days
• US Class Current: 514/3
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: C07K 14/62 Insulins

Abstract

Methods for synthesizing proinsulin polypeptides are described that include contacting a proinsulin polypeptide including an insulin polypeptide coupled to one or more peptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, and cleaving the one or more peptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate. Methods of synthesizing proinsulin polypeptide-oligomer conjugates are also provided as are proinsulin polypeptide-oligomer conjugates. Methods of synthesizing C-peptide polypeptide-oligomer conjugates and other pro-polypeptide-oligomer conjugates are also provided.

Claims

1. A method of synthesizing an insulin polypeptide-oligomer conjugate comprising:

(a) contacting a proinsulin polypeptide with an oligomer comprising a hydrophilic moiety and/or a lipophilic moiety under conditions sufficient to couple the oligomer to the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate, wherein the proinsulin polypeptide comprises;

(i) an insulin polypeptide; and

(ii) one or more non-insulin polypeptides coupled to the insulin polypeptide by peptide bond(s) capable of being cleaved to yield the insulin polypeptide; and

(b) cleaving the one or more non-insulin polypeptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate.

2. The method of claim 1 wherein:

(a) the proinsulin polypeptide comprises multiple conjugation sites; and

(b) step 1(a) yields a proinsulin polypeptide-oligomer comprising multiple oligomers.

3. The method of claim 1 wherein:

(a) the proinsulin polypeptide comprises one or more conjugation sites on the insulin polypeptide portion thereof, and

(b) step 1(a) yields a proinsulin polypeptide-oligomer comprising one or more oligomers on the insulin polypeptide portion thereof.

4. The method of claim 3 wherein step 1(a) yields a proinsulin polypeptide-oligomer conjugate wherein the non-insulin polypeptide(s) are unconjugated.

5. The method of claim 1 wherein:

(a) the proinsulin polypeptide comprises;

(i) at least one conjugation site on the insulin polypeptide portion thereof; and

(ii) at least one conjugation site on one or more non-insulin polypeptide portions thereof; and

(b) step 1(a) yields a proinsulin polypeptide-oligomer comprising;

(i) at least one oligomer coupled to the insulin polypeptide portion thereof; and

(ii) at least one oligomer coupled to one or more of the non-insulin polypeptide portion(s) thereof.

6. The method of claim 1, wherein step 1(a) comprises:

(a) contacting the oligomer with an activating agent under conditions sufficient to provide an activated oligomer capable of coupling to a nucleophilic functionality on the proinsulin polypeptide; and

(b) contacting the activated oligomer with the proinsulin polypeptide under conditions sufficient to provide the proinsulin polypeptide-oligomer conjugate.

7. The method of claim 6, wherein step 6(a) is performed in situ.

8. The method of claim 6, wherein the molar ratio of activated oligomer to proinsulin polypeptide in step 6(b) is greater than about 1:

1.

9. The method of claim 6, wherein the molar ratio of activated oligomer to proinsulin polypeptide in step 6(b) is greater than about 3:

1.

10. The method of claim 6, wherein the molar ratio of activated oligomer to proinsulin polypeptide in step 6(b) is greater than about 4:

1.

11. The method of claim 1, wherein the oligomer comprises a polyethylene glycol moiety.

12. The method of claim 1, wherein the oligomer consists essentially of a polyethylene glycol moiety.

13. The method of claim 1, wherein:

(a) the insulin polypeptide comprises an A-chain polypeptide and a B-chain polypeptide, and

(b) the one or more non-insulin polypeptides comprise a connecting peptide coupled at a first end to the C-terminus of the B-chain polypeptide and coupled at a second end to the N-terminus of the A-chain polypeptide.

14. The method of claim 13 wherein:

(a) the B-chain comprises a conjugation site at B29, and

(b) the insulin polypeptide-oligomer conjugate is conjugated at the B29 conjugation site.

15. The method of claim 13 wherein:

(a) the proinsulin polypeptide has a single lysine at B29, and

(b) the insulin polypeptide-oligomer conjugate is a B29 monoconjugate.

16. The method of claim 13, wherein the connecting peptide is a C-peptide polypeptide.

17. The method of claim 16 wherein:

(a) the C-peptide comprises a lysine, and

(b) step 1(a) yields a proinsulin polypeptide-oligomer in which the lysine(s) of the C-peptide are coupled to oligomer(s).

18. The method of claim 13, wherein the connecting peptide is C-peptide.

19. The method of claim 13, wherein the connecting peptide is devoid of lysine residues.

20. The method of claim 13, wherein the proinsulin polypeptide further comprises a leader peptide coupled to the N-terminus of the B-chain polypeptide.

21. The method of claim 20 wherein:

(a) the leader peptide comprises a lysine, and

(b) step 1(a) yields a proinsulin polypeptide-oligomer in which the lysine(s) of the leader peptide are coupled to oligomer(s).

22. The method of claim 13, wherein the leader peptide is devoid of lysine residues.

23. The method of claim 20 wherein step 1(a) yields a proinsulin polypeptide-oligomer comprising an oligomer coupled at an N-terminus of the leader peptide.

24. The method of claim 13, wherein the one or more non-insulin polypeptides further comprise a leader peptide coupled to the N-terminus of the B-chain polypeptide.

25. The method of claim 24 wherein:

(a) the leader peptide comprises a lysine, and

(b) step 1(a) yields a proinsulin polypeptide-oligomer in which the lysine(s) of the C-peptide are coupled to oligomer(s).

26. The method of claim 24, wherein the leader peptide is devoid of lysine residues.

27. The method of claim 1, wherein:

(a) the insulin polypeptide comprises an A-chain polypeptide and a B-chain polypeptide, and

(b) the C-terminus of the B-chain polypeptide is coupled to the N-terminus of the A-chain polypeptide.

28. The method of claim 1, wherein the proinsulin polypeptide is proinsulin.

29. The method of claim 1, wherein the proinsulin polypeptide is proinsulin coupled at the N-terminus of the B-chain to a leader peptide by a cleavable peptide bond.

30. The method of claim 1, wherein the insulin polypeptide is insulin.

31. The method of claim 30, wherein the oligomer is coupled to the lysine at the B29 position of the insulin.

32. The method of claim 1, wherein the insulin polypeptide is an insulin analog selected from the group consisting of Gly^A21 insulin, human;

Gly^A21 Gln^B3 insulin, human;

Ala^A21 insulin, human;

Ala^A21 Gln^B3 insulin, human;

Gln^B3 insulin, human;

Gln^B30 insulin, human;

Gly^A21 Glu^B30 insulin, human;

Gly^A21 Gln^B3 Glu^B30 insulin, human;

Gln^B3 Glu^B30 insulin, human;

Asp^B28 insulin, human;

Lys^B28 insulin, human;

Leu^B28 insulin, human;

Val^B28 insulin, human;

Ala^B28 insulin, human;

Asp^B28 Pro^B29 insulin, human;

Lys^B28 Pro^B29 insulin, human;

Leu^B28 Pro^B29 insulin, human;

Val^B28 Pro^B29 insulin, human;

Ala^B28 Pro^B29 insulin, human.

33. The method of claim 1, wherein the insulin polypeptide-oligomer conjugate is amphiphilically balanced.

34. The method of claim 1, wherein the oligomer is present as a substantially monodispersed mixture.

35. The method of claim 1, wherein the oligomer is present as a monodispersed mixture.

36. The method of claim 1, wherein the hydrophilic moiety is a polyalkylene glycol moiety.

37. The method of claim 36, wherein the polyalkylene glycol moiety is a polyethylene glycol moiety.

38. The method of claim 36, wherein the polyalkylene glycol moiety has between 1 and 50 polyalkylene glycol subunits.

39. The method of claim 36, wherein the polyalkylene glycol moiety has between 3 and 50 polyalkylene glycol subunits.

40. The method of claim 36, wherein the polyalkylene glycol moiety has between 2 and 10 polyalkylene glycol subunits.

41. The method of claim 36, wherein the polyalkylene glycol moiety has between 4 and 10 polyalkylene glycol subunits.

42. The method of claim 36, wherein the polyalkylene glycol moiety has at least 2 polyalkylene glycol subunits.

43. The method of claim 1, wherein the lipophilic moiety is an alkyl or fatty acid moiety.

44. The method of claim 1, wherein the lipophilic moiety has between 1 and 28 carbon atoms.

45. The method of claim 1, wherein the lipophilic moiety has between 2 and 24 carbon atoms.

46. The method of claim 1, wherein the lipophilic moiety has between 3 and 18 carbon atoms.

47. The method of claim 1, wherein the lipophilic moiety has between 4 and 12 carbon atoms.

48. The method of claim 1, wherein the lipophilic moiety has between 5 and 7 carbon atoms.

49. The method of claim 1, wherein the lipophilic moiety has between 4 and 14 carbon atoms.

50. The method of claim 1, wherein the cleaving of the one or more non-insulin polypeptides from the proinsulin polypeptide-oligomer conjugate comprises contacting the proinsulin polypeptide-oligomer conjugate with one or more enzymes that are capable of cleaving the bond(s) between the one or more non-insulin polypeptides and the insulin polypeptide under conditions sufficient to cleave the one or more non-insulin polypeptides from the proinsulin polypeptide-oligomer conjugate.

51. The method of claim 50, wherein the one or more enzymes are selected from the group consisting of trypsin, carboxy peptidase B, and mixtures thereof.

52. The method of claim 13, wherein the connecting peptide has a terminal amino acid residue at the first end, and wherein the cleaving of the connecting peptide from the proinsulin polypeptide-oligomer conjugate comprises:

(a) contacting the proinsulin polypeptide-oligomer conjugate with a first enzyme under conditions sufficient to provide a terminal amino acid residue-insulin polypeptide-oligomer conjugate; and

(b) contacting the terminal amino acid residue-insulin polypeptide-oligomer conjugate with a second enzyme under conditions sufficient to provide the insulin polypeptide-oligomer conjugate.

53. The method of claim 52, wherein the terminal amino acid residue is an arginine residue.

54. The method of claim 53, wherein the insulin polypeptide is insulin, and wherein the connecting peptide is human C-peptide.

55. The method of claim 52, wherein the contacting of the proinsulin polypeptide-oligomer conjugate with a first enzyme and the contacting of the terminal amino acid residue-insulin polypeptide-oligomer conjugate with a second enzyme occur substantially concurrently.

56. The method of claim 55, wherein the first enzyme and the second enzyme are provided in a mixture comprising the first enzyme and the second enzyme.

57. The method of claim 52, wherein the first enzyme is trypsin, and wherein the second enzyme is carboxy peptidase B.

58. The method of claim 1, further comprising chemically modifying one or more of the oligomer(s) of the insulin polypeptide-oligomer conjugate.

59. The method of claim 1, further comprising activating one or more of the oligomer(s) of the insulin polypeptide-oligomer conjugate.

60. The method of claim 1, further comprising lengthening one or more of the oligomer(s) of the insulin polypeptide-oligomer conjugate.

61. The method of claim 1, further comprising shortening one or more of the oligomer(s) of the insulin polypeptide-oligomer conjugate.

62. The method of claim 1, wherein the yield of insulin polypeptide-oligomer conjugate is greater than 75 percent.

63. The method of claim 1, wherein the yield of insulin polypeptide-oligomer conjugate is greater than 85 percent.

64. The method of claim 1, wherein the yield of insulin polypeptide-oligomer conjugate is greater than about 90 percent.

65. The method of claim 1, wherein the yield of insulin polypeptide-oligomer conjugate is greater than 95 percent.

66. The method of claim 1, wherein the yield of insulin polypeptide-oligomer conjugate is greater than 99 percent.

67. A method of synthesizing an insulin molecule, comprising synthesizing an insulin polypeptide-oligomer conjugate according to claim 1 and hydrolyzing the oligomer(s) from the polypeptide-oligomer conjugate to yield the insulin molecule.

68. A method of synthesizing insulin, comprising synthesizing an insulin polypeptide-oligomer conjugate according to claim 1 and hydrolyzing the oligomer(s) from the polypeptide-oligomer conjugate to yield insulin.

69. A method of synthesizing an insulin polypeptide-oligomer conjugate comprising:

(a) contacting a proinsulin polypeptide comprising an insulin polypeptide coupled to one or more non-insulin polypeptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer comprising the structure of Formula I;

A—

L_j—

G_k—

R—

G′

_m—

R′

—

G″

_n—

T  

 

(I)

wherein;

A is an activatable moiety;

L is an optional linker moiety;

G, G′ and

G″

are each optional spacer moieties;

R is a lipophilic moiety and R′

is a polyalkylene glycol moiety, or R′

is the lipophilic moiety and R is the polyalkylene glycol moiety, and wherein, (i) R and R′

are both present, or (ii) R and G are absent and L is coupled to G′

if present or to R′

if G′

is not present, or (iii) R′ and

G″

are absent and T is coupled to G′

if present or to R if G′

is not present;

T is a terminating moiety; and

j, k, m and n are individually 0 or 1;

under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate; and

(b) cleaving the one or more non-insulin polypeptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate.

70. The method of claim 69, wherein R and R′

are both present.

71. The method of claim 69, wherein R and G are absent and L is coupled to G′

if present or to R′

if G′

is not present.

72. The method of claim 71 wherein R′

is a polyethylene glycol moiety.

73. The method of claim 69, wherein R′

and G″

are absent and T is coupled to G′

if present or to R if G′

is not present.

74. The method of claim 69, wherein A is selected from the group consisting of —

C(O)—

OH, C(S)—

OH, —

C(S)—

SH, —

OH, —

SH, and NH₂.

75. The method of claim 69, wherein L is selected from the group consisting of alkyl moieties and fatty acid moieties.

76. The method of claim 69, wherein G, G′

and G″

are individually selected from the group consisting of sugar moieties, cholesterol, and glycerine moieties.

77. The method of claim 69, wherein T is selected from the group consisting of alkyl and alkoxy.

78. The method of claim 69, wherein:

A is a carboxylic acid moiety;

R is an alkyl moiety having between 3 and 8 carbon atoms;

R′

is polyethylene glycol having between 4 and 10 polyethylene glycol subunits;

T is lower alkyl or lower alkoxy; and

j, k, m and n are 0.

79. The method of claim 69, wherein:

A is a carboxylic acid moiety;

R is an alkyl moiety having between 3 and 8 carbon atoms;

R′

is polyethylene glycol having 7 polyethylene glycol subunits;

T is methoxy; and

j, k, m and n are 0.

80. A method of synthesizing an insulin polypeptide-oligomer conjugate comprising:

(a) contacting a proinsulin polypeptide comprising an insulin polypeptide coupled to one or more non-insulin polypeptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer comprising the structure of Formula II;

A—

X(CH₂)_mY(C₂H₄O)_nR  

 

(II)

wherein;

A is —

C(O)—

OH, C(S)—

OH, —

C(S)—

SH, —

OH, —

SH, or NH₂;

X is an oxygen atom or a covalent bond, with the proviso that X is not an oxygen atom when A is —

OH;

Y is an ester, an ether, a carbamate, a carbonate, or an amide bonding moiety;

m is between 0 and 30;

n is between 0 and 50;

m and n are not both 0; and

R is an alkyl moiety, a sugar moiety, cholesterol, adamantane, an alcohol moiety, or a fatty acid moiety;

under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate; and

(b) cleaving the one or more non-insulin polypeptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate.

81. The method of claim 80, wherein m is between 3 and 16.

82. The method of claim 80, wherein m is between 4 and 14.

83. The method of claim 80, wherein m is between 5 and 10.

84. The method of claim 80, wherein n is between 3 and 18.

85. The method of claim 80, wherein n is between 4 and 14.

86. The method of claim 80, wherein n is between 5 and 10.

87. The method of claim 80, wherein R is lower alkyl.

88. The method of claim 80, wherein R is C1 to C3 alkyl.

89. The method of claim 80, wherein R is methyl.

90. A method of synthesizing an insulin polypeptide-oligomer conjugate comprising:

(a) contacting a proinsulin polypeptide comprising an insulin polypeptide coupled to one or more non-insulin polypeptides by peptide bond(s) capable of being cleaved to yield the insulin polypeptide with an oligomer comprising the structure of Formula III;

A—

(CH₂)_m(OC₂H₄)_nOR  

 

(III)

wherein;

A is —

C(O)—

OH, C(S)—

OH, —

C(S)—

SH, —

OH, —

SH, or NH₂;

m is between 0 and 25;

n is between 0 and 25;

m and n are not both 0; and

R is alkyl;

under conditions sufficient to couple the oligomer to the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate; and

(b) cleaving the one or more non-insulin polypeptides from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate.

91. The method of claim 90, wherein m is between 3 and 16.

92. The method of claim 90, wherein m is between 4 and 14.

93. The method of claim 90, wherein m is between 5 and 10.

94. The method of claim 90, wherein n is between 3 and 18.

95. The method of claim 90, wherein n is between 4 and 14.

96. The method of claim 90, wherein n is between 5 and 10.

97. The method of claim 90, wherein R is lower alkyl.

98. The method of claim 90, wherein R is C₁ to C₃ alkyl.

99. The method of claim 90, wherein R is methyl.

100. A method of synthesizing an insulin polypeptide-oligomer conjugate comprising:

(a) contacting a proinsulin polypeptide comprising an insulin polypeptide having an A-chain polypeptide and a B-chain polypeptide, which comprises a lysine residue;

a connecting peptide coupled at a first end to the C-terminus of the B-chain polypeptide and coupled at a second end to the N-terminus of the A-chain polypeptide; and

a leader peptide coupled to the N-terminus of the B-chain polypeptide with an oligomer comprising the structure of Formula IV;

wherein;

m is between 0and 30;

n is between 0 and 50;

m and n are not both 0; and

R is alkyl;

under conditions sufficient to couple the oligomer to the lysine residue of the B-chain polypeptide of the insulin polypeptide portion of the proinsulin polypeptide and provide a proinsulin polypeptide-oligomer conjugate; and

(b) enzymatically cleaving the connecting peptide and the leader peptide from the proinsulin polypeptide-oligomer conjugate to provide the insulin polypeptide-oligomer conjugate.

101. The method of claim 100, wherein m is between 3 and 16.

102. The method of claim 100, wherein m is between 4 and 14.

103. The method of claim 100, wherein m is between 5 and 10.

104. The method of claim 100, wherein n is between 3 and 18.

105. The method of claim 100, wherein n is between 4 and 14.

106. The method of claim 100, wherein n is between 5 and 10.

107. The method of claim 100, wherein R is lower alkyl.

108. The method of claim 100, wherein R is C₁ to C₃ alkyl.

109. The method of claim 100, wherein R is methyl.

110. A method of synthesizing an insulin-oligomer conjugate comprising:

(a) contacting a proinsulin polypeptide, which comprises proinsulin coupled at its N-terminus to a leader peptide, with an oligomer comprising the structure of Formula V;

under conditions sufficient to couple the oligomer to the B29 lysine residue of the proinsulin and provide a proinsulin polypeptide-oligomer conjugate; and

(b) enzymatically cleaving the C-peptide and the leader peptide from the proinsulin polypeptide-oligomer conjugate to provide the insulin-oligomer conjugate.

111. The method of claim 110, wherein the enzymatically cleaving of the C-peptide and the leader peptide from the proinsulin polypeptide-oligomer conjugate comprises:

(a) contacting the proinsulin polypeptide-oligomer conjugate with a first enzyme under conditions sufficient to provide a (Arg³¹)-insulin-oligomer conjugate; and

(b) contacting the (Arg³¹)-insulin polypeptide-oligomer conjugate with a second enzyme under conditions sufficient to provide the insulin polypeptide-oligomer conjugate.

112. The method of claim 111, wherein the first enzyme is trypsin.

113. The method of claim 111, wherein the second enzyme is carboxy peptidase B.

114. A method of synthesizing an insulin polypeptide-acyl oligomer conjugate comprising enzymatically cleaving one or more non-insulin polypeptides from a proinsulin polypeptide-acyl oligomer conjugate to provide the insulin polypeptide-acyl oligomer conjugate.

115. A method of synthesizing an insulin-acyl oligomer conjugate comprising enzymatically cleaving a leader peptide and a C-peptide from a proinsulin polypeptide-acyl oligomer conjugate comprising the following structure:

116. The method of claim 115, wherein the leader peptide is devoid of lysine residues.

117. The method of claim 115, wherein the enzymatically cleaving of the C-peptide and the leader peptide from the proinsulin polypeptide-acyl oligomer conjugate comprises:

(a) contacting the proinsulin polypeptide-oligomer conjugate with a first enzyme under conditions sufficient to provide a (Arg³¹)-insulin-oligomer conjugate; and

(b) contacting the (Arg³¹)-insulin polypeptide-oligomer conjugate with a second enzyme under conditions sufficient to provide the insulin polypeptide-oligomer conjugate.

118. The method of claim 117, wherein the first enzyme is trypsin.

119. The method of claim 117, wherein the second enzyme is carboxy peptidase B.

120. A method of synthesizing a proinsulin polypeptide-oligomer conjugate comprising contacting a proinsulin polypeptide with an oligomer comprising a hydrophilic moiety and a lipophilic moiety under conditions sufficient to provide the proinsulin polypeptide-oligomer conjugate.

121. A method of synthesizing a C-peptide polypeptide-oligomer conjugate comprising:

(a) contacting a pro-C-peptide polypeptide comprising a C-peptide polypeptide coupled to one or more non-insulin polypeptides by peptide bond(s) that are cleavable to yield the C-peptide polypeptide with an oligomer under conditions sufficient to couple the oligomer to the C-peptide polypeptide portion of the pro-C-peptide polypeptide and provide a pro-C-peptide polypeptide-oligomer conjugate; and

(b) cleaving the one or more non-insulin polypeptides from the pro-C-peptide polypeptide-oligomer conjugate to provide the C-peptide polypeptide-oligomer conjugate.

122. The method of claim 121, wherein the C-peptide polypeptide is C-peptide.

123. The method of claim 121, wherein the pro-C-peptide polypeptide is a proinsulin polypeptide.

124. The method of claim 121, wherein the pro-C-peptide polypeptide is proinsulin.